Jing Christine Ye, MD, MSc

Associate Professor
UT MD Anderson Cancer Center, TX, USA (currently); University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA (during study)

Poster(s):

• P-098: Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
  Friday, September 27, 2024

• P-099: Updated Comparative Effectiveness of Talquetamab vs Real-world Physician’s Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
  Friday, September 27, 2024